Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros

Base de dados
Ano de publicação
Tipo de documento
País de afiliação
Intervalo de ano de publicação
1.
Emerg Infect Dis ; 27(11): 2971-2973, 2021 11.
Artigo em Inglês | MEDLINE | ID: mdl-34670646

RESUMO

We reconstructed the 2016-2017 Zika virus epidemic in Puerto Rico by using complete genomes to uncover the epidemic's origin, spread, and evolutionary dynamics. Our study revealed that the epidemic was propelled by multiple introductions that spread across the island, intricate evolutionary patterns, and ≈10 months of cryptic transmission.


Assuntos
Epidemias , Infecção por Zika virus , Zika virus , Evolução Molecular , Humanos , Porto Rico/epidemiologia , Zika virus/genética , Infecção por Zika virus/epidemiologia
2.
Hum Vaccin Immunother ; 20(1): 2323264, 2024 Dec 31.
Artigo em Inglês | MEDLINE | ID: mdl-38599678

RESUMO

Dengvaxia is the first dengue vaccine recommended in the United States (U.S.). It is recommended for children aged 9-16 y with laboratory-confirmed previous dengue infection and living in areas where dengue is endemic. We conducted focus groups with parents and in-depth interviews with key informants (i.e. practicing pediatricians, physicians from immunization clinics, university researchers, and school officials) in Puerto Rico (P.R.) to examine acceptability, barriers, and motivators to vaccinate with Dengvaxia. We also carried out informal meetings and semi-structured interviews to evaluate key messages and educational materials with pediatricians and parents. Barriers to vaccination included lack of information, distrust toward new vaccines, vaccine side effects and risks, and high cost of/lack of insurance coverage for laboratory tests and vaccines. Motivators included clear information about the vaccine, a desire to prevent future dengue infections, the experience of a previous dengue infection or awareness of dengue fatality, vaccine and laboratory tests covered by health insurance, availability of rapid test results and vaccine appointments. School officials and parents agreed parents would pay a deductible of $5-20 for Dengvaxia. For vaccine information dissemination, parents preferred an educational campaign through traditional media and social media, and one-on-one counseling of parents by healthcare providers. Education about this vaccine to healthcare providers will help them answer parents' questions. Dengvaxia acceptability in P.R. will increase by addressing motivators and barriers to vaccination and by disseminating vaccine information in plain language through spokespersons from health institutions in P.R.


Assuntos
Vacinas contra Dengue , Dengue , Vacinas , Criança , Humanos , Dengue/prevenção & controle , Vacinas contra Dengue/efeitos adversos , Pais , Porto Rico/epidemiologia , Estados Unidos , Vacinação/métodos , Adolescente
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA